The injection is used for treatment of hyperparathyroidism
Lupin has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market. The company has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, after having received an approval from the United States Food and Drug Administration (US FDA) earlier, Lupin said in a statement. The product is a generic version of Sanofi Genzyme’s Hectorol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, it added.
According to the IQVIA MAT October 2019 data, Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials had an annual sales of around USD 132 million in the US, Lupin said.
- Advertisement -